Answers are grounded in this paper and cite their sources.
Emerging evidence suggests that metabolic dysregulation is a central driver in the pathogenesis of pulmonary disorders, extending beyond structural or immunological failures. This review synthesises current research on the specific alterations of glucose and lipid metabolism within the context of asthma, COPD, pulmonary fibrosis and lung cancer. We highlight how these metabolic alterations fuel disease progression and identify them as promising targets for novel biomarkers and therapeutic interventions. Finally, we outline critical future directions, emphasising the need to distinguish between causality and consequence, and the importance of mapping metabolic fluxes at the single-cell level.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: